The drug, Kisunla, made by Eli Lilly, is the latest in a new class of treatments that could modestly slow cognitive decline ...

The new drug, Kisunla, has the potential to be a blockbuster for the company and generate billions in revenue. But despite ...

The FDA approved the experimental Alzheimer's drug donanemab. The drug will be sold under the brand name Kisunla.

Following this month's FDA approval of Eli Lilly’s amyloid-busting antibody Kisunla (donanemab), the Alzheimer’s disease ...

U.S. health officials have approved a new Alzheimer’s drug that can modestly slow the disease. It's only the second drug that ...

The Food and Drug Administration (FDA) has approved Kisunla ™ (donanemab-azbt) for the treatment of Alzheimer disease.

GlobalData forecasts that Leqembi and Kisunla could generate global sales of approximately $3.5 billion and $2.0 billion ...

Eli Lilly's donanemab, now Kisunla, was approved by the U.S. Food and Drug Administration for patients with early symptomatic ...

The U.S. Food and Drug Administration (FDA) approved Kisunla™ (donanemab-azbt, 350 mg/20 mL once-monthly injection for IV ...

The FDA today approved Eli Lilly’s Kisunla™ (donanemab-azbt), a once-monthly treatment for adults with early Alzheimer's ...

Eli Lilly received FDA approval for a drug to help treat Alzheimer's on Tuesday after studies showed it could help slow the ...